| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Young Sup Woo, Won-Myong Bahk, Young-Min Park, Sangkeun Chung, Bo-Hyun Yoon, Seunghee Won, Jeong Goo Lee, Hwang-Bin Lee, Won Kim, Jong-Hyun Jeong, Kwanghun Lee, Moon-Doo Ki. Effects of switching to aripiprazole from current atypical antipsychotics on subsyndromal symptoms and tolerability in patients with bipolar disorder. International clinical psychopharmacology. vol 31. issue 5. 2017-11-27. PMID:27487259. |
effects of switching to aripiprazole from current atypical antipsychotics on subsyndromal symptoms and tolerability in patients with bipolar disorder. |
2017-11-27 |
2023-08-13 |
Not clear |
| Chunsong Yang, Zilong Hao, Cairong Zhu, Qin Guo, Dezhi Mu, Lingli Zhan. Interventions for tic disorders: An overview of systematic reviews and meta analyses. Neuroscience and biobehavioral reviews. vol 63. 2016-12-13. PMID:26751711. |
six srs assessed the efficacy of atypical antipsychotics and indicated that atypical antipsychotics (i.e., risperidone, aripiprazole) could significantly improved tic symptoms compared with placebo or typical antipsychotics with less aes. |
2016-12-13 |
2023-08-13 |
Not clear |
| Soenke Boettger, Josef Jenewein, William Breitbar. Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects. Palliative & supportive care. vol 13. issue 4. 2016-04-20. PMID:25191793. |
the aim of this study was to compare the efficacy and side-effect profile of the typical antipsychotic haloperidol with that of the atypical antipsychotics risperidone, olanzapine, and aripiprazole in the management of delirium. |
2016-04-20 |
2023-08-13 |
Not clear |
| Luigi Grassi, Augusto Caraceni, Alex J Mitchell, Maria Giulia Nanni, Maria Alejandra Berardi, Rosangela Caruso, Michelle Rib. Management of delirium in palliative care: a review. Current psychiatry reports. vol 17. issue 3. 2016-02-04. PMID:25663153. |
in terms of medications, both conventional (e.g., haloperidol) and atypical antipsychotics (e.g., olanzapine, risperidone, quetiapine, aripiprazole) were shown to be equally effective in the treatment of delirium. |
2016-02-04 |
2023-08-13 |
Not clear |
| Richard C Shelto. What are the comparative benefits and harms of augmentation treatments in major depression? The Journal of clinical psychiatry. vol 76. issue 4. 2015-06-30. PMID:25919851. |
augmentation strategies, particularly the use of atypical antipsychotics to augment selective serotonin reuptake inhibitors (ssris), have proliferated over the last 15 years, and 2 atypical antipsychotics, aripiprazole and quetiapine, have received us food and drug administration approval for adjunctive therapy in treatment-resistant depression. |
2015-06-30 |
2023-08-13 |
Not clear |
| Leslie Citrome, Iftekhar Kalsekar, Ross A Baker, Tony Hebde. A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults. Current medical research and opinion. vol 30. issue 8. 2015-06-01. PMID:24666104. |
the association between atypical antipsychotics and risk factors for cardiovascular disease prompted the american diabetes association (ada) and the american psychiatric association (apa) to issue a consensus statement that categorized aripiprazole and ziprasidone as atypical antipsychotics with a lower likelihood of metabolic abnormalities. |
2015-06-01 |
2023-08-12 |
Not clear |
| Rachel Hershenberg, Daniel F Gros, Olga Brawman-Mintze. Role of atypical antipsychotics in the treatment of generalized anxiety disorder. CNS drugs. vol 28. issue 6. 2015-01-22. PMID:24794100. |
atypical antipsychotics such as quetiapine, aripiprazole, olanzapine, and risperidone have been shown to be helpful in addressing a range of anxiety and depressive symptoms in individuals with schizophrenia and schizoaffective disorders, and have since been used in the treatment of a range of mood and anxiety disorders. |
2015-01-22 |
2023-08-13 |
human |
| Kate McKeag. Aripiprazole: a review of its use in the treatment of manic episodes in adolescents with bipolar I disorder. CNS drugs. vol 28. issue 2. 2015-01-13. PMID:24399490. |
unlike other currently available atypical antipsychotics that primarily have varying degrees of dopamine d2 receptor antagonism, aripiprazole is a partial agonist at d2 and serotonin 5-ht1a receptors, which may explain differences in tolerability profiles. |
2015-01-13 |
2023-08-12 |
human |
| Kate McKeag. Aripiprazole: a review of its use in the treatment of manic episodes in adolescents with bipolar I disorder. CNS drugs. vol 28. issue 2. 2015-01-13. PMID:24399490. |
data comparing the use of atypical antipsychotics in the treatment of mania in adolescents with bipolar i disorder are limited, but evidence shows that aripiprazole provides a valuable additional therapeutic option for use in this population. |
2015-01-13 |
2023-08-12 |
human |
| Yoshihiro Seki, Takahiro A Kato, Akira Monji, Yoshito Mizoguchi, Hideki Horikawa, Mina Sato-Kasai, Daigo Yoshiga, Shigenobu Kanb. Pretreatment of aripiprazole and minocycline, but not haloperidol, suppresses oligodendrocyte damage from interferon-γ-stimulated microglia in co-culture model. Schizophrenia research. vol 151. issue 1-3. 2014-07-29. PMID:24100191. |
we have reported that not only atypical antipsychotics with dopamine d2 receptor (d2r) antagonism but also aripiprazole, a unique antipsychotic drug with d2r partial agonism, inhibit microglial activation in vitro. |
2014-07-29 |
2023-08-12 |
Not clear |
| Priya Khanna, Tao Suo, Katja Komossa, Huaixing Ma, Christine Rummel-Kluge, Hany George El-Sayeh, Stefan Leucht, Jun Xi. Aripiprazole versus other atypical antipsychotics for schizophrenia. The Cochrane database of systematic reviews. issue 1. 2014-07-01. PMID:24385408. |
aripiprazole versus other atypical antipsychotics for schizophrenia. |
2014-07-01 |
2023-08-12 |
Not clear |
| B L Amann, R Wesuls, R Landin Romero, H Grunz. [De-escalation and atypical antipsychotics in the treatment of acute mania]. Fortschritte der Neurologie-Psychiatrie. vol 81 Suppl 1. 2013-12-23. PMID:23681717. |
furthermore, the efficacy and tolerability of atypical antipsychotics in acute mania, such as olanzapine, zotepine, risperidone, quetiapine, ziprasidone, aripiprazole, paliperidone and asenapine are discussed. |
2013-12-23 |
2023-08-12 |
Not clear |
| Shigenori Tadokor. [Aripiprazole as "dopamine sensitivity stabilizer"]. Nihon rinsho. Japanese journal of clinical medicine. vol 71. issue 4. 2013-09-25. PMID:23678600. |
aripiprazole (ari) is one of atypical antipsychotics used for the treatment of schizophrenia all over the world, owing to its tolerability and ability to keep antipsychotic effect for an extended period of time. |
2013-09-25 |
2023-08-12 |
Not clear |
| Jooyoung Oh, Jhin Goo Chang, Seul Bi Lee, Dong-Ho Song, Keun-Ah Cheo. Comparison of aripiprazole and other atypical antipsychotics for pediatric bipolar disorder: a retrospective chart review of efficacy and tolerability. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 11. issue 2. 2013-09-11. PMID:24023551. |
comparison of aripiprazole and other atypical antipsychotics for pediatric bipolar disorder: a retrospective chart review of efficacy and tolerability. |
2013-09-11 |
2023-08-12 |
Not clear |
| Jooyoung Oh, Jhin Goo Chang, Seul Bi Lee, Dong-Ho Song, Keun-Ah Cheo. Comparison of aripiprazole and other atypical antipsychotics for pediatric bipolar disorder: a retrospective chart review of efficacy and tolerability. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 11. issue 2. 2013-09-11. PMID:24023551. |
this study compared the efficacy and tolerability of aripiprazole with that of other atypical antipsychotics by examining patients with pediatric bipolar disorder (pbd) at a child and adolescent psychiatric clinic in a university hospital in korea. |
2013-09-11 |
2023-08-12 |
Not clear |
| Hua Jin, Pei-an Betty Shih, Shahrokh Golshan, Sunder Mudaliar, Robert Henry, Danielle K Glorioso, Stephan Arndt, Helena C Kraemer, Dilip V Jest. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization. The Journal of clinical psychiatry. vol 74. issue 1. 2013-04-15. PMID:23218100. |
to compare longer-term safety and effectiveness of the 4 most commonly used atypical antipsychotics (aripiprazole, olanzapine, quetiapine, and risperidone) in 332 patients, aged > 40 years, having psychosis associated with schizophrenia, mood disorders, posttraumatic stress disorder, or dementia, diagnosed using dsm-iv-tr criteria. |
2013-04-15 |
2023-08-12 |
Not clear |
| Priya Khanna, Katja Komossa, Christine Rummel-Kluge, Heike Hunger, Sandra Schwarz, Hany George El-Sayeh, Stefan Leuch. Aripiprazole versus other atypical antipsychotics for schizophrenia. The Cochrane database of systematic reviews. issue 2. 2013-03-28. PMID:23450570. |
aripiprazole versus other atypical antipsychotics for schizophrenia. |
2013-03-28 |
2023-08-12 |
Not clear |
| Anagha Nadkarni, Iftekhar Kalsekar, Min You, Robert Forbes, Tony Hebde. Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy. ClinicoEconomics and outcomes research : CEOR. vol 5. 2013-02-05. PMID:23378778. |
to compare total medical costs and utilization over a 12-month period in commercially insured patients receiving fda-approved adjunctive atypical antipsychotics (aripiprazole, olanzapine, or quetiapine) for depression. |
2013-02-05 |
2023-08-12 |
Not clear |
| Norio Yasui-Furukori, Ayako Kaneda, Norio Sugawara, Tetsu Tomita, Sunao Kanek. Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. Journal of psychopharmacology (Oxford, England). vol 26. issue 6. 2013-01-15. PMID:21616975. |
effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. |
2013-01-15 |
2023-08-12 |
Not clear |
| Kunio Yu. [Useful pharmacologic treatment in impaired social interaction in autism spectrum disorders]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica. vol 114. issue 8. 2013-01-08. PMID:23012855. |
in addition, atypical antipsychotics aripiprazole and ssri fluvoxamine were useful in treating some aspects of social relatedness or the core deficits of communication and socialization. |
2013-01-08 |
2023-08-12 |
Not clear |